Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$128.00
▲(4.30% Upside)
Action:Reiterated
Date:08/19/26
Overall score is held back primarily by very weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity). Offsetting factors include moderately positive technical momentum and supportive corporate catalysts (BLA acceptance and expanded financing capacity), while valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Regulatory path and clinical differentiation
FDA acceptance creates a defined path toward a potential first commercial product. The randomized trial showed a 52% reduction in progression or death risk and more than doubled median progression-free survival versus placebo.
Negative Factors
No established commercial revenue
The absence of recurring product revenue leaves the company dependent on financing, partnerships, or future regulatory success. Until a therapy is approved and launched, revenue visibility remains weak and the business lacks a self-sustaining commercial base.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory path and clinical differentiation
FDA acceptance creates a defined path toward a potential first commercial product. The randomized trial showed a 52% reduction in progression or death risk and more than doubled median progression-free survival versus placebo.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.81B
Dividend YieldN/A
Average Volume (3M)317.27K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue Growth-100.00%
EPS Growth19.23%
CountryUS
Employees110
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.88
Shares Outstanding14,717,660
10 Day Avg. Volume232,714
30 Day Avg. Volume317,272
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$266.67Price Target Upside117.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.41
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic ca...
How the Company Makes Money
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company and does not have a stable, product-based commercial revenue stream typical of mature pharmaceutical companies. The company’s cash inflows generally come from (1) collaboration an...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 1.30M | 200.00K | 1.80M | 2.19M | 7.23M |
| Gross Profit | -1.68M | -1.18M | -2.08M | 609.00K | -107.99M | 7.23M |
| EBITDA | -120.45M | -125.37M | 1.70B | -206.69M | -125.82M | -76.55M |
| Net Income | -138.18M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 154.22M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 133.34M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.34M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 207.20M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -52.98M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.87M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.89M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | 20.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 78.67M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Positive
122.72
Price Trends
92.99
Positive
97.89
Positive
87.34
Positive
Market Momentum
6.74
Negative
76.60
Negative
91.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 122.72 is above the 20-day moving average (MA) of 95.22, above the 50-day MA of 92.99, and above the 200-day MA of 87.34, indicating a bullish trend. The MACD of 6.74 indicates Negative momentum. The RSI at 76.60 is Negative, neither overbought nor oversold. The STOCH value of 91.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 89 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $2.18B | -13.11 | -28.66% | ― | -28.56% | 10.25% | |
56 Neutral | $4.05B | -22.67 | -17.49% | ― | 101.28% | 2.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $1.81B | -14.11 | 1893.60% | ― | -100.00% | 19.23% | |
52 Neutral | $1.96B | -14.51 | -72.07% | ― | -69.78% | -106.07% | |
48 Neutral | $1.93B | -205.88 | -2.35% | ― | 20.19% | ― | |
45 Neutral | $1.38B | -5.09 | -47.27% | ― | -65.40% | -164.71% |
* General Sector Average
INBX
Inhibrx Biosciences Inc
125.34
97.46
349.57%
XNCR
Xencor
28.44
20.39
253.29%
ZYME
Zymeworks
29.31
14.47
97.47%
IMTX
Immatics
9.43
4.15
78.60%
ABCL
AbCellera Biologics
12.24
7.94
184.65%
IMCR
Immunocore Holdings
37.12
4.88
15.14%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Inhibrx Biosciences Expands Credit Facility to $500 Million
Positive
Jul 17, 2026
On July 15, 2026, Inhibrx Biosciences Inc. amended its Loan and Security Agreement with Oxford Finance, expanding its credit facility to as much as $500 million and adding a new $325 million tranche. The company received an immediate $100 million ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
Positive
Jun 15, 2026
On June 15, 2026, Inhibrx Biosciences Inc. announced that the U.S. Food and Drug Administration accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondros...
Executive/Board ChangesShareholder Meetings
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
Neutral
Jun 3, 2026
Inhibrx Biosciences Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, in a virtual format, with approximately 79% of the 14.6 million eligible common shares present or represented by proxy, underscoring strong shareholder particip...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.